Regeneron Q2 2026: Revenue Surges 17% to $4.29B on Record Dupixent, Sanofi Balance Repaid, New $3B Buyback
REGN sits 34% above its 52-week low of $541.
Summary
Regeneron crushed Q2 2026 estimates with $4.29B in revenue (up 17% YoY) and non-GAAP EPS of $14.29, driven by record Dupixent sales. The Sanofi development balance is fully repaid, unlocking an additional ~$250M in quarterly profit sharing. A new $3B buyback was authorized, and the FDA approved gene therapy Otarmeni.
Key Events · Earnings and Guidance · REGN
-
Q2 Revenue and EPS Blowout
Revenue of $4.29B (+17% YoY) and non-GAAP EPS of $14.29 beat consensus by 12% and nearly 40%, respectively, fueled by Dupixent global sales of $5.998B (+38% YoY).
-
Sanofi Development Balance Fully Repaid
The Sanofi development balance was fully repaid as of June 30, 2026, meaning the $253M quarterly reimbursement that reduced collaboration revenue will cease starting Q3 2026, directly boosting Regeneron's share of profits.
-
New $3B Share Repurchase Program
Board authorized a new $3.0 billion share repurchase program in April 2026; $2.534B remained available as of June 30. Combined with the quarterly $0.94 dividend, capital returns are accelerating.
-
Pipeline: FDA Approves Otarmeni, Fianlimab Phase 3 Miss
FDA approved gene therapy Otarmeni for hearing loss; Lynozyfic showed 100% hematologic complete response in amyloidosis. However, fianlimab + Libtayo missed its primary endpoint in first-line metastatic melanoma vs. pembrolizumab.
Analysis · REGN · Life Sciences
A massive Q2 beat saw revenue climb 17% year-over-year to $4.29 billion, powered by Dupixent global sales soaring 38% to nearly $6 billion. Non-GAAP EPS of $14.29 crushed consensus by almost 40%. With the Sanofi development balance now fully repaid, an additional $253 million in quarterly profit sharing will flow directly to Regeneron starting in Q3. The company also authorized a new $3 billion share repurchase program and disclosed U.S. government pricing agreements that lock in Most-Favored-Nation pricing while exempting Regeneron from Section 232 tariffs through 2029. On the pipeline front, the FDA approved the gene therapy Otarmeni, though fianlimab missed its Phase 3 primary endpoint in first-line melanoma. Multiple legal proceedings advanced, including a favorable ruling that dismissed most of Amgen's counterclaims in the EYLEA biosimilar litigation. A temporary manufacturing interruption in Limerick, Ireland pressured gross margins to 78% from 83% a year ago, but production has since normalized. The quarter underscores Dupixent's dominance and Regeneron's ability to convert top-line growth into shareholder returns, even as EYLEA franchise erosion and pipeline setbacks warrant monitoring.
At the time of this filing, REGN was trading at $724.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.9B. The 52-week trading range was $541.00 to $821.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.